Table 1.
Cell line | Type | HLA-DR expression, MFI | CD20 expression, MFI | C2-2b-2b |
20-2b-2b |
734-2b-2b |
hL243γ4p |
hL243γ4p + 734-2b-2b |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50, nM | TI, fold | Imax, % | IC50, nM | TI, fold | Imax, % | IC50, nM | Imax, % | IC50, nM | Imax, % | IC50, nM | Imax, % | ||||
Daudi | BL | 2092* | 500* | 3 × 10−5 | 117 | 95 | 1 × 10−4 | 25 | 95 | 3 × 10−3 | 95 | 5.13 | 67 | 4 × 10−3 | 95 |
Raji | BL | 2317* | 391* | 0.35 | 23 | 70 | 3.89 | 2 | 60 | 8.13 | 62 | > 20† | 45 | 0.56 | 70 |
Ramos | BL | 373* | 516* | 0.90 | > 20 | 82 | 7.76 | > 3 | 70 | > 20† | 35 | > 20† | 25 | > 20† | 43 |
WSU-FSCCL | FL | 2030* | 37* | 0.19 | > 100 | 80 | > 20† | 22 | > 20† | 24 | 0.37 | 85 | 0.46 | 73 | |
Jeko-1 | MCL | 539* | 250* | 0.10 | > 200 | 100 | 1.1 | > 20 | 59 | > 20† | 21 | 0.4 | 98 | 0.18 | 90 |
Granta-519 | MCL | 1797* | 805* | 4.0 | > 5 | 66 | > 20† | 31 | > 20† | 14 | 6.4 | 59 | 3.5 | 66 | |
CAG | MM | 2804* | 4* | 3 × 10−3 | 55 | 98 | 0.13 | 1 | 85 | 0.16 | 85 | 20 | 52 | 0.08 | 98 |
NCI-H929 | MM | 4‡ | 1‡ | 0.13 | 1 | 98 | 0.14 | 1 | 98 | 0.11 | 98 | > 20† | 0 | 0.12 | 98 |
KMS12-PE | MM | 940* | 3* | 0.63 | 6 | 80 | 3.28 | 1 | 72 | 3.9 | 68 | > 20† | 27 | 0.97 | 76 |
KMS12-BM | MM | 1502* | 318* | 0.51 | > 50 | 73 | 7.82 | > 3 | 55 | > 20† | 22 | 3.47 | 59 | 0.61 | 73 |
MM1R | MM | 79‡ | 1‡ | 2 × 10−3 | 10 | 100 | 0.05 | 0.5 | 95 | 0.02 | 97 | > 20† | 10 | 0.03 | 98 |
KMS11 | MM | 615* | 3* | 1.85 | > 10 | 66 | > 20† | 21 | > 20† | 24 | 2.19 | 62 | 1.72 | 66 | |
OPM6 | MM | 41‡ | 2‡ | 4 × 10−3 | 2 | 99 | 8 × 10−3 | 1 | 99 | 8 × 10−3 | 99 | > 20† | 6 | 8 × 10−3 | 99 |
U266 | MM | 223‡ | 2‡ | 9 × 10−4 | 22 | 96 | 0.02 | 1 | 93 | 0.02 | 92 | > 20† | 10 | 8 × 10−3 | 91 |
HC-1 | HCL | 5501* | 1079* | 0.08 | 134 | 91 | 0.47 | 23 | 69 | 10.72 | 59 | 0.59 | 89 | 0.49 | 89 |
Kasumi-3 | AML | 445* | 5* | 6 × 10−3 | 18 | 87 | 0.10 | 1 | 78 | 0.11 | 76 | > 20† | 0 | 0.09 | 81 |
GDM-1 | AML | 553* | 4* | 8 | > 3 | 68 | > 20† | 11 | > 20† | 35 | > 20† | 0 | > 20† | 35 | |
MEC-1 | CLL | 2421* | 271* | 1.2 | 17 | 78 | 20 | > 1 | 50 | > 20† | 34 | > 20† | 30 | 20 | 50 |
WAC | CLL | 799* | 211* | 2.19 | > 10 | 79 | > 20† | 26 | > 20† | 20 | > 20† | 37 | 5.89 | 60 | |
REH | ALL | 2583* | 15* | 2.14 | 12 | 67 | 13.80 | 2 | 57 | 26.30 | 52 | 7.46 | 64 | 4.95 | 64 |
697 | ALL | 1108* | 13* | > 20† | 40 | > 20† | 40 | > 20† | 23 | > 20† | 18 | > 20† | 34 | ||
RS4/11 | ALL | 2522* | 3* | > 20† | 41 | > 20† | 39 | > 20† | 36 | > 20† | 19 | > 20† | 41 |
Cultures were grown in 48-well plates until the density of untreated cells increased a minimum of 10-fold (3-7 days).
MFI indicates mean fluorescent intensity; IC50, concentration (nM) resulting in 50% growth inhibition compared with untreated cells; TI, targeting index = fold reduction in EC50 compared with nontargeted IFNα (734-2b-2b); Imax, maximal percentage decrease in viable cells compared with untreated cells; BL, Burkitt lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; HCL, hairy cell leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; and ALL, acute lymphoblastic leukemia.
Previously reported in Rossi et al.15
Treatment failed to reach 50% inhibition.
Previously reported in Rossi et al.14